- Proteomics (PIQ) places its shares in a trading halt pending the release of a capital raising announcement
- The company will remain in the halt until Monday, August 15, or when the announcement is released, whichever occurs first
- On August 9, Proteomics signed a binding letter of intent with Sonic Healthcare USA to introduce PIQ’s PromarkerD test for diabetic kidney disease to the United States
- The letter of intent outlines the terms and expectation for how Proteomics and Sonic will work together to test patients and subject to conditions, the contract is expected to be completed by December 31
- Shares in Proteomics last traded at 98 cents on August 10
Proteomics (PIQ) has placed its shares in a trading halt pending the release of a capital raising announcement.
The company will remain in the halt until Monday, August 15, or when the announcement is released, whichever occurs first.
Proteomics is yet to disclose how much it intends to raise or what it will use the funds for once received.
On August 9, Proteomics signed a binding letter of intent with Sonic Healthcare USA to introduce PromarkerD to the United States.
The letter of intent outlines the terms and expectation for how Proteomics and Sonic will work together to test patients in the US.
Subject to conditions, Proteomics and Sonic are aiming to finalise the contract by December 31.
PromarkerD is a simple, low-cost blood test that uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before symptoms appear.
It allows patients to apply preventative measures before kidney damage occurs, leading to better outcomes for the patient and simplified care for physicians.
Shares in Proteomics last traded at 98 cents on August 10. The company has a $103.6 million market cap.